The state of Massachusetts currently has 31 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Clarifying the Optimal Application of SLT Therapy Trial
NCT04967989
Recruiting
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Massachusetts Eye and Ear, Boston, Massachusetts +2 locations
Conditions: Glaucoma and Ocular Hypertension
Register for Updates
A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension
NCT05798923
Recruiting
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pulmonary Hypertension
Register for Updates
CHW Intervention to Improve Nutrition Security of Patients with Hypertension
NCT06358417
Recruiting
The goal of this study is to implement and evaluate a randomized pilot study of a 4-month Nutrition-enhanced community health worker (CHW) intervention for primary care patients with nutrition insecurity and poorly controlled hypertension. The nutrition intervention will be added to the pre-existing Massachusetts General Hospital CHW hypertension (Basic CHW) program that provides hypertension education, coaching about adherence to medications and primary care visits, and home BP cuffs and promot... Read More
Gender:
ALL
Ages:
Between 21 years and 99 years
Trial Updated:
11/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypertension, Nutrition, Healthy, Food Insecurity, Community Health Worker
Register for Updates
Global Paradise System US Post Approval Study
NCT06297291
Recruiting
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: The Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Register for Updates
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
NCT04811092
Recruiting
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Tufts Medical Center - PPDS ( Site 1014), Boston, Massachusetts +1 locations
Conditions: Pulmonary Arterial Hypertension
Register for Updates
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250
Recruiting
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/11/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Pulmonary Hypertension
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
10/09/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Pediatric Pulmonary Hypertension
Register for Updates
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT03626688
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Tufts Medical Center, Boston, Massachusetts +2 locations
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Register for Updates
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974
Recruiting
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/25/2024
Locations: Boston, Boston, Massachusetts
Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Register for Updates
MR Antagonist and LSD1
NCT04840342
Recruiting
Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (\~30%) of the essenti... Read More
Gender:
ALL
Ages:
17 years and above
Trial Updated:
08/06/2024
Locations: Brigham and Women's, Boston, Massachusetts
Conditions: Hypertension, Mineralocorticoid Excess
Register for Updates
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
NCT04835857
Recruiting
(1) To compare cuff-less wrist wearable radial artery blood pressure measurements utilizing ViTrack(developed by Dynocardia) to the cuff based commercially available blood pressure device, in healthy volunteers with normal or high blood pressure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/05/2024
Locations: Dynocardia Inc, Newton, Massachusetts
Conditions: Hypertension, Healthy
Register for Updates
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
06/27/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Register for Updates